Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

Here, we present a brief review of some insights we have gained into the dimerization of dopamine and serotonin ... of these mutants with the wild-type receptor does not result in any effect ...

because they do not cause behavioral signs associated with activation of either normosensitive or supersensitive postsynaptic dopamine D 2 receptors (e.g., increased locomotion in reserpinized ...

DOI: 10.1038/s41593-024-01819-9 Nicolas X. Tritsch, Motivating interest in D3 dopamine receptors, Nature Neuroscience (2024). DOI: 10.1038/s41593-024-01820-2 ...

Increasing calcium restored dopamine release, showing that the problem lies in nicotinic receptor function. "Our findings suggest that behavioral inflexibility in autism arises from deficits in ...

The mechanism of action of clozapine in schizophrenia is unknown, however, it is thought to be mediated through antagonism of the dopamine type 2 (D2) and the serotonin type 2A (5-HT2A) receptors.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Bromocriptine is unique in that it does not have a specific receptor that mediates its action on glucose and lipid metabolism. Rather, its effects are mediated via resetting of dopaminergic and ...